155 related articles for article (PubMed ID: 31980731)
1. Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells.
Danylesko I; Jacoby E; Yerushalmi R; Shem-Tov N; Besser MJ; Vernitsky H; Marcu-Malina V; Shimoni A; Avigdor A; Nagler A
Leukemia; 2020 Jul; 34(7):1939-1942. PubMed ID: 31980731
[No Abstract] [Full Text] [Related]
2. Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells.
Qu C; Li Z; Kang L; Wang Y; Dai H; Yin J; Chen G; Zhu M; Yao L; Xu T; Tian X; Xu Y; Chen J; Zhu X; Yu L; Wu D; Tang X
Bone Marrow Transplant; 2019 Jul; 54(7):1138-1140. PubMed ID: 30631098
[No Abstract] [Full Text] [Related]
3. Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19.
Plesa A; Labussière-Wallet H; Hayette S; Salles G; Thomas X; Sujobert P
Haematologica; 2019 Oct; 104(10):e487-e488. PubMed ID: 31197067
[No Abstract] [Full Text] [Related]
4. [The Immunophenotypical features of t (8; 21) (q22; q22) acute myeloid leukemia].
Pan X; Li J; Xia X; Geng M; Wang A; Zhu M; Chen L; Guo Y; Xue Y
Zhonghua Xue Ye Xue Za Zhi; 2001 Jun; 22(6):313-5. PubMed ID: 11877092
[TBL] [Abstract][Full Text] [Related]
5. Role of CD19 and specific KIT-D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities.
Wang B; Yang B; Ling Y; Zhang J; Hua X; Gu W; Yan F
Cancer Med; 2021 Feb; 10(3):1091-1102. PubMed ID: 33382538
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
8. Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission.
Buonamici S; Ottaviani E; Visani G; Bonifazi F; Fiacchini M; Baccarani M; Martinelli G
Haematologica; 2004 Jan; 89(1):103-5. PubMed ID: 14754613
[No Abstract] [Full Text] [Related]
9. Translocation (3;21;8)(q21;q22;q22) in a patient with acute myeloid leukemia. A case report and review of prognostic indicators.
Giles FJ; Kanemaki TJ; Schreck RR; Qasabian L; Fuerst MP; Lim SW
Cancer Genet Cytogenet; 1998 Jul; 104(1):66-9. PubMed ID: 9648562
[TBL] [Abstract][Full Text] [Related]
10. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of trisomy 6 in an adult acute myeloid leukemia with t(8;21).
Choi J; Song J; Kim SJ; Choi JR; Kim SJ; Min YH; Park TS; Cho SY; Kim MJ
Cancer Genet Cytogenet; 2010 Oct; 202(2):141-3. PubMed ID: 20875878
[No Abstract] [Full Text] [Related]
12. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.
Walter K; Cockerill PN; Barlow R; Clarke D; Hoogenkamp M; Follows GA; Richards SJ; Cullen MJ; Bonifer C; Tagoh H
Oncogene; 2010 May; 29(20):2927-37. PubMed ID: 20208555
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
[TBL] [Abstract][Full Text] [Related]
15. Acute leukemia with t(8;21) can express T-lineage-associated markers.
Orazi A; Kotylo P; Neiman RS
Blood; 1992 Oct; 80(7):1855-6. PubMed ID: 1285763
[No Abstract] [Full Text] [Related]
16. Pseudo-Chediak-Higashi anomaly in acute myeloid leukemia with t (8;21).
Bozkaya IO; Yarali N; Sac RU; Tavil B; Kara A; Azik F; Tunç B
J Pediatr Hematol Oncol; 2012 Apr; 34(3):242. PubMed ID: 22441711
[No Abstract] [Full Text] [Related]
17. Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
Wimmer J; Hurstel R
Blood; 2021 May; 137(18):2564. PubMed ID: 33956065
[No Abstract] [Full Text] [Related]
18. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
19. A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia.
Zampini M; Bisio V; Leszl A; Putti MC; Menna G; Rizzari C; Pession A; Locatelli F; Basso G; Tregnago C; Pigazzi M
Br J Haematol; 2018 Oct; 183(2):298-301. PubMed ID: 28961307
[No Abstract] [Full Text] [Related]
20. Significance of spatial organization of chromosomes in the progression of acute myeloid leukemia.
Tian X; Wang Y; Chen D; Ke X; Ma W
Chin J Cancer; 2017 Apr; 36(1):40. PubMed ID: 28427460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
